Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;119(3):371-380.
doi: 10.1111/bju.13760. Epub 2017 Jan 24.

Guideline of guidelines: non-muscle-invasive bladder cancer

Solomon L Woldu  1 , Aditya Bagrodia  1 , Yair Lotan  1
Affiliations
Review

Guideline of guidelines: non-muscle-invasive bladder cancer

Solomon L Woldu et al. BJU Int. 2017 Mar.

Abstract

Non-muscle-invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, but this definition represents a spectrum of disease with a variable clinical course, notable for significant risk of recurrence and potential for progression. Management involves risk-adapted strategies of cystoscopic surveillance and intravesical therapy with the goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, but adherence to management principles among practising urologists is reportedly low. We review four major organizational guidelines on NMIBC: the American Urological Association (AUA)/Society of Urologic Oncology (SUO), European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), and National Institute for Health and Care Excellence (NICE) guidelines.

Keywords: #BladderCancer; #blcsm; guidelines; management; non-muscle-invasive bladder cancer.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

Dr. Lotan is involved in research for Photocure, Abbott Laboratories, Cepheid Inc., Pacific Edge Ltd., GenomeDx Bioscience Inc., FKD Therapies Oy and consults for Photocure, KMD Biomarker Diagnostics, BioCancell Therapeutics Ltd.

References

    1. Ferlay JIS, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: IARC CancerBase No.11 [Internet] GLOBOCAN 2012 v19. 2014 [cited 2013 Sept 2016]; Available from: http://globocan.iarc.fr. - PubMed
    1. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. European urology. 2013 Feb;63:234–41. - PubMed
    1. van Rhijn BW, Burger M. Bladder cancer: Low adherence to guidelines in non-muscle-invasive disease. Nature reviews Urology. 2016 Aug 31; - PubMed
    1. Torreggiani A, Colombo R, Gontero P, Lapini A, Sanseverino R, Serretta V. Clinical practice and adherence to the diagnosis and treatment of NMIBC guidelines: a report of a recognition based clinical cases study. Urologia. 2015 Jan-Mar;82:58–70. - PubMed
    1. Witjes JA, Palou J, Soloway M, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS) BJU international. 2013 Oct;112:742–50. - PMC - PubMed

Publication types